Citius Oncology (CTOR) Treasury Shares (2021 - 2024)

Citius Oncology (CTOR) has reported Treasury Shares for 4 consecutive years, with $4.3 million the latest figure, recorded in Q2 2024.

• On a quarterly basis, Treasury Shares fell 34.67% year-over-year to $4.3 million in Q2 2024; TTM through Jun 2024 was $4.3 million, a 34.67% decrease from a year earlier, with the FY2023 full-year figure at $6.6 million, changed 0.0% from the prior year.
• Treasury Shares was $4.3 million for Q2 2024 at Citius Oncology, roughly flat from $4.3 million in the prior quarter.
• Over five years, Treasury Shares peaked at $6.6 million in Q4 2021 and troughed at $4.3 million in Q1 2024.
• A 4-year average of $6.0 million and a median of $6.6 million in 2021 frame the typical range for Treasury Shares.
• Across the five-year window, Treasury Shares changed 0.0% in 2022 and sank 34.67% in 2024, its largest moves.
• Over 4 years, Treasury Shares stood at $6.6 million in 2021, then changed by 0.0% to $6.6 million in 2022, then changed by 0.0% to $6.6 million in 2023, then slumped by 34.67% to $4.3 million in 2024.
• The last three Treasury Shares figures came in at $4.3 million (Q2 2024), $4.3 million (Q1 2024), and $6.6 million (Q4 2023), per Business Quant data.